Nature oncology deals
Restoring immune surveillance to tackle age-related diseases.Deal volume Average projected value Average upfront payments Fig.
Oncology dealmaking in 2020
Note however that all editorial decisions are made by a team of full-time professional editors , who are PhD .Oncology-related deals and M&As dominate the landscape– Oncology-focused deals accounted for a large proportion of global biopharma licensing, .oncology drug licensing deals larger than $1 billion in value, 15 were for IO-related assets, and 9 of those were for multi-targeted approaches such as bispecific antibodies and antibody–drug con-
Volume 13 Issue 1, March 2019
Trends in oncology dealmaking Meletios Verras/Thinkstock/iStock
Small-molecule deals as a class
Articles in 2022
Nature Reviews Clinical Oncology has an external advisory board.The exponential, global expansion of radiotheranostics in oncology stems from its potential to target and eliminate tumour cells with minimal adverse effects, owing to a mechanism .
The top 10 partnerships . Data are from Cortellis Deals Intelligence from Clarivate.Nature Biotechnology 41 , 1365–1372 ( 2023) Cite this article. 12 December 2023.
Checkforupdates. Nature Reviews Clinical Oncology 21 , 167 ( 2024) Cite this article.
Oncology remains the strongest focus by volume (18% of deals) and spending (43%) in the billion-dollar group, thanks mostly to the Pfizer–Seagen deal.56 billion deal signed in May 2021 to gain an exclusive license to Agenus’s AGEN1777.1038/s41571-022-00652-y.
From the ESMO Congress 2023
Trends driving licensing, collaborations and joint ventures included: a maturation of deals toward co-development and co-commercialization, the increasingly .Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United .Within the oncology community, growing interest exists in using data from the real world to address clinical and policy-relevant questions that cannot be answered with data from clinical trials .
Oncology dealmaking in 2020
The EU’s green deal to restore biodiversity, clean the continent’s soil, air and water, and mitigate climate breakdown is at high risk of being killed off, the co-president .
Antibody dealmaking driven by oncology
The Sun rises in the landscape of treatment for patients ovarian carcinoma, inspired by the Review on p820.In addition to the continued prominence of I-O assets in dealmaking, here we highlight two other trends in partnering in the oncology field: deals to bring innovative oncology . The context for oncology dealmaking in 2022 is very different from just a few years ago. In 2021, global .Radiotherapy is a key treatment modality in oncology that contributes to ~40% of cures 1, and its importance is underpinned by the fact that the technology for delivering radiation is continually .
Jamie Munro and Helen Dowden
Oncology deal upfront payments 3. Nature Biotechnology 42 , 362–366 ( 2024) Cite this article. Sanofi made a particularly big splash by announcing a pair of deals to add to its stable of oncology partnerships (among which is a
Trends in neuroscience dealmaking
Biopharma M&A is back and IPOs are possible, but most biotechs aren’t out of the woods. Patients with advanced-stage non-small-cell lung cancer (NSCLC .The deal could establish the merged company as one of the largest in the oncology field, by combining Bristol-Myers Squibb’s extensive immuno-oncology (IO) .Our assessment shows that the implementation of this tool in less-developed regions could reduce the estimated proportion of undiagnosed cases of colorectal cancer .Looking at the past decade of oncology dealmaking (Fig.Trends driving licensing, collaborations and joint ventures included: a maturation of deals toward co-development and co-commercialization, the increasingly global nature of deal-making, continued energy around oncology therapeutics and pharma companies seeking footholds within the enabling technologies underpinning next .BioPharma Dealmakersis an online platform, print publication, and webcast format specifically designed to appeal to industry scientists, partnering and licensing executives, .
Manquant :
nature oncologyWhile no other therapy area comes close to matching oncology in terms of deal volume (as we highlighted earlier this year; BioPharma Dealmakers B3–B6; March 2018), neuroscience is among the .
In this feature, authors at Clarivate Analytics explore the trends in recent oncology deals.Oncology-focused partnerships drove record-level licensing deals in 2021 as companies looked to gain access to novel therapeutic targets and platforms. This represents growth of almost 40% from 2021, despite a widely .
Immuno-oncology dominates big pharma’s deal agenda
The $74 billion acquisition of Celgene by BMS is the top deal of any type in 2019 (Fig.Immuno-oncology (IO) was prominent once again in oncology licensing deals, with IO deals representing 65% of the total pro- jected deal value and 44% of transactions.
Manquant :
dealsIn 2022, the total potential value for antibody-focused deals reached a new high of $57. 1) and one of the largest ever. Oncology deal milestone payments 3. Most of the highest-value deals involving antibodies (Table 1) were in the oncology .Repotrectinib effective in ROS1-fusion-positive NSCLC.Our investment firm, Aglaia, has built a database of 190 full-acquisition deals involving oncology therapeutics ventures for which deal economics were disclosed (Box 1). Pfizer acquired Seagen in a US$43 . Oncology royalty rates Chapter 4 - Leading oncology deals and .Real-world data (RWD) and real-world evidence (RWE) from heterogeneous data sources has the potential to transform oncology research, especially when coupled with artificial intelligence (AI). 2022 Aug;19 (8):534-550.Stepping to the exit
Biopharma’s appetite for high-value partnerships continued into 2021, as 55 deals reached the billion-dollar-plus mark in 2021, compared with 53 in this category in 2020.
Global Dealmaking in a Global Indication: Oncology Partnering
Immuno-oncology, with only slight exaggeration, utterly dominates biopharma’s current deal agenda: in announcements timed to coincide with the start of the annual JP Morgan Healthcare Conference .Drug licensing deals in 2020 with total projected deal value greater than or equal to $1 billion. 11 November 2023.
Top ten oncology partnerships
The spate of deals announced on just a single day—January 11— helps to illustrate the breadth of pharma’s interest in, and the value of, biotech companies e’ arly-stage immuno-oncology research pro - grams.The Northern Territory government has signed a major deal to buy fracked gas from the Beetaloo basin south of Katherine a year after it gave the green light for .
Manquant :
nature oncologyCancer-targeting antibody–drug conjugates drive dealmaking frenzy. As in 2017, this year’s ESMO Congress brought many members of the oncology community together in Madrid, this time with >33,000 delegates attending in person or online. A detailed survey by Springer Nature of 100 oncologists provided revealing insights about . Up-front payments are down, overall deal values are down, and deal .Oncology is currently the leading area for dealmaking, driven by immuno-oncology, which accounted for 32 of the 35 multibillion-dollar oncology licensing deals of the last five . Katja Ovchinnikova1, Jannis 2 Born 2, Panagiotis .The FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on . We were able to retrieve .The largest deal was signed between AbbVie and Genmab in June 2020; the two compa-nies collaborated to develop Genmab’s pipeline of bispecific molecules that target CD3 . Bispecific antibodies continue immuno-oncology drive Recent deals involving bispecific antibodies illustrate the growing . Multi-target proteins capture the second highest accumulated deal value, where disclosed.Oncology dealmaking in 2021 Credit: Brain light / Alamy Stock
‘IO’ indicates whether any asset in the deal involves immuno-oncology. Using mRNA–lipid nanoparticles . The merger brought together BMS’s extensive immuno-oncology (IO) pipeline .By Dylan Kissane.
